Correction: Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Saved in:
Format: | Article |
---|---|
Language: | English |
Published: |
BMJ Publishing Group
2023-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/1/e005414corr1.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
by: Sandip P. Patel, et al.
Published: (2025-01-01) -
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
by: Da Xu, et al.
Published: (2025-02-01) -
Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
by: Yingjun Xie, et al.
Published: (2018-01-01) -
CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers
by: Chiara Tuccilli, et al.
Published: (2018-01-01) -
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
by: Zongyu Liu, et al.
Published: (2025-01-01)